652 results on '"Lake, Richard"'
Search Results
102. Dynamic versus static biomarkers in cancer immune checkpoint blockade: unravelling complexity
103. Additional file 2: Table S2. of Consistent gene expression profiles in MexTAg transgenic mouse and wild type mouse asbestos-induced mesothelioma
104. Additional file 4: Table S4. of Consistent gene expression profiles in MexTAg transgenic mouse and wild type mouse asbestos-induced mesothelioma
105. Additional file 5: Table S5. of Consistent gene expression profiles in MexTAg transgenic mouse and wild type mouse asbestos-induced mesothelioma
106. Additional file 3: Table S3. of Consistent gene expression profiles in MexTAg transgenic mouse and wild type mouse asbestos-induced mesothelioma
107. Additional file 1: Table S1. of Consistent gene expression profiles in MexTAg transgenic mouse and wild type mouse asbestos-induced mesothelioma
108. Chapter 24 - Immune Stimulatory Features of Classical Chemotherapy
109. Transient Treg depletion enhances therapeutic anti‐cancer vaccination
110. Chemotherapy and immunotherapy: mapping the road ahead
111. PD-L1 on peripheral blood T lymphocytes is prognostic in patients with non-small cell lung cancer (NSCLC) treated with EGFR inhibitors
112. Combining Prime-Boost Anti-tumour Vaccination with Debulking Surgery for the Treatment of Solid Tumours
113. The impact of sub-cellular localization and dose of tumor antigen on the efficiency cross-presentation
114. Optimising regulatory T cell (Treg) depletion in combination with chemotherapy for enhanced anti-tumour immunity
115. EORTC and CALGB prognostic models, but not neutrophil-to-lymphocyte ratio, are prognostic in unselected patients with newly diagnosed malignant mesothelioma
116. Programmed Death Ligand 2 in Cancer-Induced Immune Suppression
117. Consistent gene expression profiles in MexTAg transgenic mouse and wild type mouse asbestos-induced mesothelioma
118. Novel insights into the pathophysiology and treatment of malignant pleural mesothelioma
119. Dexamethasone co-medication in cancer patients undergoing chemotherapy causes substantial immunomodulatory effects with implications for chemo-immunotherapy strategies
120. Network analysis of immunotherapy-induced regressing tumours identifies novel synergistic drug combinations
121. Strong spontaneous tumor neoantigen responses induced by a natural human carcinogen
122. Restoration of defective cross-presentation in tumors by gemcitabine
123. A better way for a cancer cell to die
124. Prescription drugs: uses and effects
125. Transient Treg depletion enhances therapeutic anti-cancer vaccination.
126. Transfection of the Chloramphenicol-Acetyltransferase Gene into Eukaryotic Cells Using Diethyl-Aminoethyl (DEAE)-Dextran
127. Unmasking tumor cell immunogenicity by chemotherapy: implications for therapy
128. Tumor-infiltrating dendritic cells exhibit defective cross-presentation of tumor antigens, but is reversed by chemotherapy
129. The efficacy of tumor debulking surgery is improved by adjuvant immunotherapy using imiquimod and anti-CD40
130. Effect of NSAIDS and COX-2 inhibitors on the incidence and severity of asbestos-induced malignant mesothelioma: Evidence from an animal model and a human cohort
131. Chemotherapy Enhances Cross-Presentation of Nuclear Tumor Antigens
132. Neoadjuvant anti-tumor vaccination prior to surgery enhances survival
133. Statins Do Not Alter the Incidence of Mesothelioma in Asbestos Exposed Mice or Humans
134. Comment on “Drug Discovery: Turning the Titanic”
135. Dietary Vitamin D Supplementation Does Not Reduce the Incidence or Severity of Asbestos-Induced Mesothelioma in a Mouse Model
136. TRANSP modelling of experimentally measured fast particle redistribution and losses on MAST
137. Synergistic Effect of CTLA-4 Blockade and Cancer Chemotherapy in the Induction of Anti-Tumor Immunity
138. The identification of the fouling mechanism during the crossflow filtration of a model fermentation broth
139. Peripheral CD8+ T cell proliferation is prognostic for patients with advanced thoracic malignancies
140. Loss of antigen cross-presentation after complete tumor resection is associated with the generation of protective tumor-specific CD8+T-cell immunity
141. Tumor cells, rather than dendritic cells, deliver antigen to the lymph node for cross-presentation
142. The Use of Agonistic Anti-CD40 Therapy in Treatments for Cancer
143. The Antioxidants Vitamins A and E and Selenium Do Not Reduce the Incidence of Asbestos-Induced Disease in a Mouse Model of Mesothelioma
144. Heat-Shocking of Murine Malignant Mesothelioma Cells Enhances Their Effectiveness as an Autologous Anti-Tumour Vaccine
145. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma
146. MexTAg mice exposed to asbestos develop cancer that faithfully replicates key features of the pathogenesis of human mesothelioma
147. Indications for Operation on the Mastoid and Tympanic Antrum
148. HANDBOOK OF THE DISEASES OF THE EAR
149. PULMONARY CHANGES RELATED TO CARDIOSPASM*
150. Licensing and Professional Function
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.